CRF Announces Late Breaking Trials And First Report Investigations To Be Presented At TCT 2012

Clinical Trial Findings Will Feature Research Breakthroughs in Interventional Cardiology

NEW YORK, Sept. 14, 2012 /PRNewswire-USNewswire/ -- The Cardiovascular Research Foundation (CRF) has announced the late breaking trials and first report investigations that will be presented at next month's Transcatheter Cardiovascular Therapeutics (TCT) 2012 scientific symposium. TCT, the world's premier educational meeting specializing in interventional cardiovascular medicine, will take place October 22 – 26 in Miami, Florida.

The studies selected will shed new light on the effectiveness and safety of minimally invasive techniques, pharmaceuticals, technologies and devices that show potential to treat or prevent cardiovascular disease, one of the leading causes of death globally. Late-breaking clinical trials and first report investigations will be presented in the Main Arena and highlighted during press conferences scheduled for Wednesday, October 24, Thursday, October 25, and Friday, October 26.

WEDNESDAY OCTOBER 24, 2012

Late Breaking Trials

• FAME 2 Cost-effectiveness: A Prospective, Randomized Trial Evaluating the Cost-effectiveness of FFR-Guided PCI in Patients with Stable Coronary Artery Disease
• MASTER: A Prospective, Randomized Trial of a PET Micronet Mesh-Covered Stent vs. Standard Stents in Patients with ST-Segment Elevation Myocardial Infarction
• ISAR-LEFT MAIN 2: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents in Patients with Unprotected Left Main Disease

First Report Investigations

• PARTNER Cohort B Three Year: Clinical and Echocardiographic Outcomes from a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement in "Inoperable" Patients
• TRILOGY ACS Angiographic Cohort: A Prospective, Randomized Trial of Prasugrel vs. Clopidogrel in Patients with Non-ST-Segment Elevation ACS Who Are Medically Managed After Coronary Angiography
• A Prospective, Randomized Trial of Nitinol Stents vs. Balloon Angioplasty in Obstructive Popliteal Lesions

THURSDAY, OCTOBER 25

Late Breaking Trials

• RESPECT: A Prospective, Randomized Trial of PFO Closure vs. Medical Therapy in Patients with Cryptogenic Stroke
• The PC Trial: A Prospective, Randomized Trial of PFO Closure vs. Medical Therapy in Patients with Cryptogenic Embolism
• A Prospective, Randomized Trial of Sliding-Scale Hydration for Prevention of Contrast Nephropathy

First Report Investigations

• ADAPT-DES One Year: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel Hyporesponsiveness on Patient Outcomes
• AIDA STEMI MRI: Cardiac MRI Substudy from a Prospective, Randomized Trial of Intracoronary Abciximab in Patients with ST-Segment Elevation Myocardial Infarction
• A Prospective, Randomized Trial of Post-Conditioning in Patients with ST-Segment Elevation Myocardial Infarction

FRIDAY, OCTOBER 26, 2012

Late Breaking Trials

• XIMA: A Prospective, Randomized Trial of Everolimus-Eluting Stents vs. Bare-Metal Stents in Octogenarians
• ISAR-DESIRE 3: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons vs. Paclitaxel-Eluting Stents vs. Balloon Angioplasty for Restenosis of "Limus"-Eluting Coronary Stents
• STEMI-RADIAL: A Prospective, Randomized Trial of Radial vs. Femoral Access in Patients with ST-Segment Elevation Myocardial Infarction

To view the complete TCT agenda, visit: http://www.tctconference.com/agenda.html.

Receive updates on Twitter: http://twitter.com/TCTConference.

About CRF
The Cardiovascular Research Foundation (CRF) is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education. Since its inception in 1991, CRF has played a major role in realizing dramatic improvements in the lives of countless numbers of patients by establishing the safe use of new technologies and therapies in interventional cardiovascular medicine.

Transcatheter Cardiovascular Therapeutics (TCT) is the annual scientific symposium of the Cardiovascular Research Foundation. TCT gathers leading medical researchers and clinicians from around the world to present and discuss the latest developments in the field.

For more information, visit www.crf.org.

SOURCE Cardiovascular Research Foundation